HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy
- PMID: 18670217
- DOI: 10.1097/QAD.0b013e328305bd77
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy
Abstract
Objective: An important pending question is whether temporary highly active antiretroviral therapy during primary HIV infection can influence viral rebound dynamics and the subsequently established viral setpoint, through preservation and enhancement of HIV-1-specific immune responses, or through other mechanisms.
Methods: We included all patients from two prospective studies who underwent a single treatment interruption while being well suppressed on highly active antiretroviral therapy. One group started highly active antiretroviral therapy during primary HIV infection, and the other group started it during chronic HIV infection with CD4 cell counts above 350 cells/microl. Data were collected up to 48 weeks from treatment interruption. The median time to viral rebound was analysed for three levels of viraemia: 50, 500 and 5000 copies HIV-RNA/ml plasma.
Results: The median time to viral rebound was significantly longer in primary HIV infection patients (n = 24) than in chronic HIV infection patients (n = 46): 8 versus 4 weeks (P < 0.001 for all three endpoints). In two primary HIV infection patients, no rebound of plasma HIV-1 RNA over 50 copies/ml occurred. In the first 4 weeks after treatment interruption, CD4+ T-cell counts declined with a median of -5.0 cells/microl blood per week in the primary HIV infection group and -45 cells/microl blood per week in the chronic HIV infection group (P < 0.05). From week 4 to 48, the decline in CD4+ T-cell count was similar in both groups.
Conclusion: Plasma viral load and CD4 dynamics after a single interruption of highly active antiretroviral therapy were different for primary HIV infection and chronic HIV infection patients. Viral rebound is delayed or absent and early CD4 cell count decline after treatment interruption is less pronounced in primary HIV infection patients.
Similar articles
-
Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.HIV Med. 2005 Jan;6(1):7-12. doi: 10.1111/j.1468-1293.2005.00257.x. HIV Med. 2005. PMID: 15670246
-
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319
-
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.AIDS. 2007 Jan 11;21(2):169-78. doi: 10.1097/QAD.0b013e328011033a. AIDS. 2007. PMID: 17197807 Clinical Trial.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13377-8. doi: 10.1073/pnas.212518999. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370421 Free PMC article. Review. No abstract available.
Cited by
-
Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):364-369. doi: 10.1097/QAI.0000000000001393. J Acquir Immune Defic Syndr. 2017. PMID: 28394856 Free PMC article.
-
Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound.J Infect Dis. 2021 Dec 1;224(11):1925-1934. doi: 10.1093/infdis/jiab223. J Infect Dis. 2021. PMID: 33963757 Free PMC article.
-
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.Hum Vaccin Immunother. 2012 Oct;8(10):1425-30. doi: 10.4161/hv.21616. Epub 2012 Oct 1. Hum Vaccin Immunother. 2012. PMID: 23095869 Free PMC article. Clinical Trial.
-
Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana.AIDS Res Hum Retroviruses. 2021 Jan;37(1):16-23. doi: 10.1089/AID.2020.0097. Epub 2020 Oct 19. AIDS Res Hum Retroviruses. 2021. PMID: 32935556 Free PMC article.
-
Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life.J Virol. 2020 Jan 31;94(4):e01519-19. doi: 10.1128/JVI.01519-19. Print 2020 Jan 31. J Virol. 2020. PMID: 31776265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials